Literature DB >> 15677864

Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease.

Geneviève Leuba1, Gwenaëlle Wernli, André Vernay, Rudolf Kraftsik, M Hasan Mohajeri, Krishan D Saini.   

Abstract

In this study, we quantitatively investigated the expression of beta-site amyloid precursor protein cleaving enzyme (BACE) in the entorhinohippocampal and frontal cortex of Alzheimer's disease (AD) and old control subjects. The semiquantitative estimation indicated that the intensity of BACE overall immunoreactivity did not differ significantly between AD and controls, but that a significantly stronger staining was observed in the hippocampal regions CA3-4 compared to other regions in both AD patients and controls. The quantitative estimation confirmed that the number of BACE-positive neuronal profiles was not significantly decreased in AD. However, some degeneration of BACE-positive profiles was attested by the colocalization of neurons expressing BACE and exhibiting neurofibrillary tangles (NFT), as well as by a decrease in the surface area of BACE-positive profiles. In addition, BACE immunocytochemical expression was observed in and around senile plaques (SP), as well as in reactive astrocytes. BACE-immunoreactive astrocytes were localized in the vicinity or close to the plaques and their number was significantly increased in AD entorhinal cortex. The higher amount of beta-amyloid SP and NFT in AD was not correlated with an increase in BACE immunoreactivity. Taken together, these data accent that AD progression does not require an increased neuronal BACE protein level, but suggest an active role of BACE in immunoreactive astrocytes. Moreover, the strong expression in controls and regions less vulnerable to AD puts forward the probable existence of alternate BACE functions. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677864     DOI: 10.1159/000083496

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  18 in total

1.  Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.

Authors:  Daniel Paris; Nowell J Ganey; Vincent Laporte; Nikunj S Patel; David Beaulieu-Abdelahad; Corbin Bachmeier; Amelia March; Ghania Ait-Ghezala; Michael J Mullan
Journal:  J Neuroinflammation       Date:  2010-03-08       Impact factor: 8.322

2.  Expression of reticulon 3 in Alzheimer's disease brain.

Authors:  H Kume; Y Konishi; K S Murayama; F Kametani; W Araki
Journal:  Neuropathol Appl Neurobiol       Date:  2009-04       Impact factor: 8.090

3.  Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.

Authors:  Sébastien S Hébert; Katrien Horré; Laura Nicolaï; Aikaterini S Papadopoulou; Wim Mandemakers; Asli N Silahtaroglu; Sakari Kauppinen; André Delacourte; Bart De Strooper
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-23       Impact factor: 11.205

Review 4.  Astroglia in Alzheimer's Disease.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Jose Julio Rodriguez-Arellano; Robert Zorec
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 5.  Can BACE1 inhibition mitigate early axonal pathology in neurological diseases?

Authors:  Xiao-Xin Yan; Chao Ma; Wei-Ping Gai; Huaibin Cai; Xue-Gang Luo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes.

Authors:  N Rajasekar; Chandishwar Nath; Kashif Hanif; Rakesh Shukla
Journal:  Mol Neurobiol       Date:  2015-12-11       Impact factor: 5.590

Review 7.  Astrocyte signaling and neurodegeneration: new insights into CNS disorders.

Authors:  Liliana Brambilla; Francesca Martorana; Daniela Rossi
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

8.  Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease.

Authors:  Timo Grimmer; Panagiotis Alexopoulos; Amalia Tsolakidou; Liang-Hao Guo; Gjermund Henriksen; Behrooz H Yousefi; Hans Förstl; Christian Sorg; Alexander Kurz; Alexander Drzezga; Robert Perneczky
Journal:  ScientificWorldJournal       Date:  2012-01-03

9.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

10.  The Alzheimer's disease beta-secretase enzyme, BACE1.

Authors:  Sarah L Cole; Robert Vassar
Journal:  Mol Neurodegener       Date:  2007-11-15       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.